Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476813 | 0.99 | KDM4E (0.52) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3819196 | 0.92 | KDM4E (0.52) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3814640 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3819280 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL14030221 | 0.89 | KDM4E (0.43) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3819327 | 0.88 | GSK3B (0.44) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL4388689 | 0.87 | KDM4E (0.50) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3820142 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL3809995 | 0.87 | KDM4E (0.41) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL335178 | 0.86 | KDM4E (0.42) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR (HR) | 2008-12-18 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | CYP51A1, TLR5, MALT1 | KDM4E 2612/4885ALDH1A1 2370/4885LMNA 2596/4885 |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | IL17A, IL15, CASP14 | KDM4E 1422/4885ALDH1A1 3802/4885LMNA 3341/4885 |
| US-20080312167-A1 | 4'' Amino Linked Macrolides Useful for the Treatment of Microbial Infections | IL4I1, IL4, TLR5 | KDM4E 1535/4885ALDH1A1 2548/4885LMNA 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.